Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal…
COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on…
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The…
Oslo, Norway, 20 May 2026 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian…
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 28 April 2026 – 6 PM CET Disclosure of transparency notification from BlackRock, Inc.…
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study…
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen…
Männedorf, Switzerland, March 17, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a strategic collaboration with NVIDIA…